May 7th, 2021

November 13, 2020
Dylann Cohn-Emery

Treatment with the investigation agent INBRX-109 induced responses and decreased the tumor burden in a cohort of patients with chondrosarcoma, according to interim efficacy and safety findings a phase 1 trial in…

Inhibrx Granted Fast Track Designation for INBRX-109 for the Treatment of Unresectable or Metastatic Conventional Chondrosarcoma Patients Registration-enabling study expected to begin dosing in the second or third quarter of this year

April 30th, 2021

Elena Cojocaru,
Christopher Wilding,
Bodil Engelman,
Paul Huang &
Robin L. Jones

Current Molecular Biology Reports volume 6, pages1–9(2020)Cite this article

Is the IDH Mutation a Good Target for Chondrosarcoma Treatment? |…

Abstract

Dioxins are ubiquitous and persistent environmental contaminants whose background levels are still reason for concern. There is mounting evidence from both epidemiological and experimental studies that paternal exposure to the most potent…

Sebastien passed away July 14, 2020 from dedifferentiated chondrosarcoma. This narrative was written and submitted by his sister Stephanie Desjardins.

In April 2019, my brother was diagnosed with a chondrosarcoma of chest wall on the right side…

April 29th, 2021

Empowering Patients: Speak Up For Your Health
Tuesday, May 11, 2021 at 12:00 PM ET

Please consider registering to a special information session where our panel of experts will discuss the importance of advocating for patient care and treatment….

April 24th, 2021

The Bone Cancer Research Trust is hosting a free Support & Information Webinar. It features Carol Hughes who will provide a presentation on Managing the fear of recurrence, On Thursday 29th April

We know that when treatment for primary bone…

April 23rd, 2021

Proton therapy induces biologic response to attack treatment-resistant cancers February 17, 2021

ROCHESTER, Minn. — Mayo Clinic researchers have developed a novel proton therapy technique to more specifically target cancer cells that resist…

April 10th, 2021

In the last decade, researchers have come to realize that tumors harbor bits of extrachromosomal DNA that can drive malignancy.

Paul Mischel Apr 1, 2021
338

In the spring of 2012, my colleagues and I began to notice something strange in tumor…

The purpose of this study is to learn whether combining lenvatinib and pembrolizumab is a safe and effective treatment for patients with metastatic soft tissue sarcomas that cannot be surgically removed. This study will include patients with…